Synthesis of fucosylated oligosaccharide LNFP-V
By introducing specific glycosyltransferase genes into E. coli cells, and using lactose to synthesize human milk oligosaccharide LNFP-V, the problem of producing complex HMOs in the prior art is solved, and safe and economical and efficient production is achieved.
CN113166789BActive Publication Date: 2025-03-28GLYCOM AS
7 Cites 0 Cited by
Patent Information
- Application Number
- CN201980080607.6
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Priority Date
- 2018-12-04
- Filing Date
- 2019-12-04
- Publication Date
- 2025-03-28
- Estimated Expiration
- 2039-12-04
AI Technical Summary
Technical Problem
The prior art is difficult to effectively produce complex structures of human milk oligosaccharides (HMOs) such as lactoyl-N-fucosaccharide V (LNFP-V), especially under economic and safe conditions.
Method used
Genes encoding β1,3-N-acetylglucosamine transferase, β1,3-galactosyltransferase and α1,3/4-fucosyltransferase were introduced to synthesize LNFP-V in lactose by using genetically modified E. coli cells.
Benefits of technology
The efficient production of LNFP-V under safe and cost-effective conditions is achieved, solving the challenge of producing complex HMOs in the prior art.
✦ Generated by Eureka AI based on patent content.
Abstract
The present invention provides a method for producing LNFP-V by using recombinant bacterial cell biotechnology. LNFP-V is produced by using a polypeptide having α1,3 / 4-fucosyltransferase activity, which comprises or consists of an amino acid sequence having at least 90% sequence identity with the amino acid sequence of SEQ ID No. 1 or 3.
Need to check novelty before this filing date? Find Prior Art